Abeona Therapeutics Inc (NASDAQ:ABEO) SVP Brendan M. O'malley Sells 10,470 Shares

Abeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) SVP Brendan M. O'malley sold 10,470 shares of Abeona Therapeutics stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $6.76, for a total value of $70,777.20. Following the transaction, the senior vice president now owns 378,245 shares of the company's stock, valued at $2,556,936.20. This trade represents a 2.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Abeona Therapeutics Trading Up 4.0%

NASDAQ ABEO traded up $0.26 during trading on Friday, hitting $6.74. 938,085 shares of the company's stock traded hands, compared to its average volume of 639,223. The stock has a fifty day moving average of $5.51 and a two-hundred day moving average of $5.57. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. Abeona Therapeutics Inc has a 12-month low of $3.93 and a 12-month high of $7.32. The firm has a market cap of $344.80 million, a P/E ratio of -2.51 and a beta of 1.68.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.11. As a group, sell-side analysts expect that Abeona Therapeutics Inc will post -1.16 EPS for the current year.

Hedge Funds Weigh In On Abeona Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP bought a new position in shares of Abeona Therapeutics during the fourth quarter valued at approximately $520,000. Jane Street Group LLC grew its holdings in shares of Abeona Therapeutics by 894.8% during the fourth quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company's stock valued at $732,000 after buying an additional 118,262 shares during the last quarter. Trexquant Investment LP purchased a new stake in shares of Abeona Therapeutics during the fourth quarter valued at approximately $382,000. Northern Trust Corp grew its holdings in shares of Abeona Therapeutics by 6.6% during the fourth quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company's stock valued at $1,030,000 after buying an additional 11,478 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp purchased a new stake in shares of Abeona Therapeutics during the fourth quarter valued at approximately $362,000. Institutional investors own 80.56% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on ABEO shares. Stifel Nicolaus lowered their price target on shares of Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a report on Friday, May 16th. Alliance Global Partners reissued a "buy" rating on shares of Abeona Therapeutics in a report on Thursday, May 15th. Wall Street Zen cut shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 15th. HC Wainwright boosted their price target on shares of Abeona Therapeutics from $15.00 to $20.00 and gave the company a "buy" rating in a research report on Wednesday, April 30th. Finally, Oppenheimer started coverage on shares of Abeona Therapeutics in a research report on Monday. They set an "outperform" rating and a $19.00 price target for the company. One analyst has rated the stock with a sell rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $19.25.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.